A PAK1 inhibitor, FRAX597, when combined with gemcitabine, led to a synergistic inhibition of pancreatic cancer proliferation in vitro and a further reduced tumour growth in vivo [97]. Here, PAK1 is linked to pancreatic neoplasm.